| My Account | Subscribe | Contact Us | Donate |
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
If you are a physician, educator and medical professional who focus on the treatment of diabetes, then this is the must have resource for you.
Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.
Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.
Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
You can cancel your newsletter subscription at anytime by clicking "Unsubscribe" on the bottom of any newsletter you receive
Then enter your new email address in the above form and click "Subscribe"
Latest Medications Research Articles
The lawsuit is the first time that a government entity has entered court against Glaxo.
Santa Clara County, the largest county in Northern California (nearly 1.9 million people), has filed a federal lawsuit against pharmaceutical company GlaxoSmithKline, alleging that Glaxo knowingly sold its type 2 diabetes drug Avandia for several years despite indications the drug causes heart attacks and strokes.
Avandia, which began selling in 1999 and has been a major source of revenue for Pennsylvania-based Glaxo, has been under fire in recent years as evidence accumulated that the drug has been a major factor in thousands of deaths from cardiovascular events. (This Diabetes Health article discusses recent news surrounding Avandia in more detail.)
The county's lawsuit is the first time that a government entity has entered court against Glaxo. Santa Clara, which spent $2 million on Avandia from 1999 through 2007 for indigent patients, is claiming that Glaxo's silence about harmful side effects forced the county to have to spend more money, unknowingly, to treat the heart problems Avandia caused.
The county says that while it has been planning the lawsuit for some time, a recent U.S. Senate subcommittee report criticizing both Glaxo and the Food and Drug Administration for their handling of Avandia's problems was the final spur to action.
Santa Clara's suit seeks compensation not only for itself but also for California diabetes patients and healthcare providers who have used or prescribed Avandia.
Avandia is Glaxo's trade name for rosiglitazone, a member of the family of anti-diabetes drugs known as thiazolidinediones. TZDs are drugs that increase the body's sensitivity to insulin.
* * *
Source:
Categories: Health Insurance, Medications, Medications Research, Type 2 Issues
0 comments -
Mar 9, 2010 -
Email to a Friend
Send a link to this page to your friends and colleagues.